3D-Printed Pills and Polypills: How Personalized Medicine Could Finally Go Mainstream

A Decade of Research, One Clear Goal

Dr Georgina Marsh, head of pharmacy and prescribing at the University of Suffolk, has been studying 3D printing in pharmaceuticals since 2013. Her work focuses on a problem most patients know well: standard tablet doses do not fit everyone. If 10 milligrams is not quite right and 15 milligrams is too much, the patient is stuck. Personalized medicine aims to close that gap, and 3D printing is the manufacturing method that makes it practical.

Marsh explains that traditional tableting produces drugs in fixed doses after large clinical trials determine what works for the average patient. 3D printing changes the equation by allowing a pharmacy to manufacture a 12.5 milligram tablet on demand for a specific patient. The technology does not aim to replace mass manufacturing for common drugs, but it could become the right answer for rare diseases, pediatric cases, and patients who need very specific combinations of medications.

Polypills: More Than One Drug in One Tablet

Traditional tableting can produce at most two drugs in a single tablet as separate layers. 3D printing removes that ceiling. A printed polypill can contain multiple compartments, each holding a different drug at its precise dose. For elderly patients taking a handful of tablets every day, a single printed polypill could replace several. Marsh says the potential impact on adherence and quality of life is significant.

Her team is also exploring 3D-printed wound dressings that conform to the exact shape of a patient's wound. For diabetic patients with chronic wounds that take months to heal, a perfectly fitted dressing could speed recovery and reduce discomfort.

The Regulatory Hurdle Is Real

The FDA approved the first 3D-printed tablet, Spiritam, in 2015. Only one or two others have progressed to routine clinical use since then. The challenge is quality control. Mass-produced medicines let manufacturers test a sample from a batch of thousands and assume the rest meet specifications. With 3D-printed medicines, every tablet could theoretically differ, requiring continuous monitoring rather than periodic batch testing.

Regulators are aware of the challenge and have started issuing guidance, but many questions remain. Until those frameworks mature, 3D-printed medicines will likely stay in niche applications: rare disease treatments, customized pediatric doses, and hospital-based compounding.

Looking Ahead

Marsh believes 3D-printed medicines could become commonplace for the right use cases within 20 to 30 years. She will present her research at Ipswich's first TEDx talk in October, with plans to livestream the session on the global TEDx platform. The University of Suffolk's new integrated master's pharmacy course launching this September will also include personalized medicine and 3D printing in its curriculum, training the next generation of pharmacists to work with technology that is not yet widely available but is closer than most people think.

Source: Yahoo News UK / University of Suffolk